Funding for this research was provided by:
PharmaEssentia Corporation
University of Miyazaki
Article History
Received: 4 February 2024
Revised: 27 May 2024
Accepted: 3 June 2024
First Online: 1 July 2024
Declarations
:
: KS received research funding from PharmaEssentia Corporation, PharmaEssentia Japan KK, Chugai Pharmaceutical Co., Ltd., AbbVie GK, Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Taisho Pharmaceutical Co., Ltd; funding for medical writing and article processing charges from PharmaEssentia Japan KK; and honoraria from Novartis Pharma KK and Takeda Pharmaceutical Co., Ltd. AQ is the chief medical officer of PharmaEssentia. NK is a board member of and received funding for medical writing and article processing charges from PharmaEssentia Japan KK; research funding from PharmaEssentia Corporation, Takeda Pharmaceutical Co., Ltd., and Meiji Seika Pharma Co., Ltd.; grants from Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd., PharmaEssentia Japan KK, Chugai Pharmaceutical Co., Ltd., and Perseus Proteomics Inc.; consulting fees from Japan Tobacco Inc., Torii Pharmaceutical Co., Ltd., and PharmaEssentia Japan KK; and honoraria from Novartis Pharma KK and Takeda Pharmaceutical Co., Ltd. KK received research funding from PharmaEssentia Corporation; funding for medical writing and article processing charges from PharmaEssentia Japan KK; and honoraria from Novartis Pharma KK, Takeda Pharmaceutical Co., Ltd., PharmaEssentia Japan KK, Sanofi KK, and AbbVie GK.